share_log
  • Headlines
  • LENZ Therapeutics Q3 2024 GAAP EPS $(0.38) Beats $(0.47) Estimate, Cash, Cash Equivalents And Marketable Securities Of $217.2M With Cash Runway Anticipated To Extend To Post-Launch Positive Operating Cash Flow

LENZ Therapeutics Q3 2024 GAAP EPS $(0.38) Beats $(0.47) Estimate, Cash, Cash Equivalents And Marketable Securities Of $217.2M With Cash Runway Anticipated To Extend To Post-Launch Positive Operating Cash Flow

Benzinga ·  Nov 6 20:05

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.47) by 19.15 percent.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated